Akcea Connect UK
Akcea Therapeutics UK
- Akcea Therapeutics US

About us
News
Rare diseases
For healthcare professionals
For patients & families

The information contained in this section of the site is intended for UK healthcare professionals only. Please confirm you are a healthcare professional to continue.

I confirm I am a UK healthcare professional

Continue
Go back

News

Tegsedi™▼ (inotersen) to be made available on the NHS in England for people with hATTR amyloidosis

Published date: 16/04/2019

AKCUK-071 | September 2020

Back to news listing

Recent Posts

WAYLIVRA▼® (volanesorsen), the first and only therapy for FCS, an ultra-rare and life-threatening condition, to be available on the NHS in England
Akcea response to draft negative guidance from NICE for WAYLIVRA▼® (volanesorsen), the only therapy for FCS, a devastating and ultra-rare disease
Tegsedi®▼ (inotersen) to be made available on the NHS in Scotland for people with rare hATTR amyloidosis
NICE issues final guidance for Tegsedi®▼ (inotersen) for hATTR amyloidosis
Akcea and Ionis Announce Authorisation of WAYLIVRA▼® (volanesorsen) in the European Union

Terms of use
Cookie policy
Privacy policy
Careers
Contact us

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ Adverse events should also be reported to Akcea Therapeutics UK Ltd:
Email: MedInfoUK@akceatx.com
Telephone: +44 (0) 330 159 0174

© 2020, all rights reserved.
AKC-056-002 | September 2020

Akcea Therapeutics UK Ltd,

Regus Building
Brooklands Business Park
Wellington Way
Weybridge
Surrey
KT13 0TT
UK

+44 (0)1932 871862
UKinfo@akceatx.com
MedInfoUK@akceatx.com